EGFR and non-small cell lung carcinoma: Elevated PDK1 expression has been detected in patients with resistance to Osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI) that selectively targets the EGFR T790M mutation in non-small cell lung cancer (NSCLC) 136.